List of Excipients in Branded Drug TIVICAY PD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ViiV Healthcare Company	TIVICAY PD	dolutegravir sodium	49702-255	CALCIUM SULFATE DIHYDRATE	2030-06-08
ViiV Healthcare Company	TIVICAY PD	dolutegravir sodium	49702-255	CELLULOSE, MICROCRYSTALLINE	2030-06-08
ViiV Healthcare Company	TIVICAY PD	dolutegravir sodium	49702-255	CROSPOVIDONE	2030-06-08

TIVICAY PD Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 21, 2026

TIVICAY PD is ViiV Healthcare’s pediatric dolutegravir product, supplied as 5 mg tablets for oral suspension. Its excipient system is designed around rapid dispersion in a small volume of water, acceptable taste, dose flexibility, tablet robustness, and use in children from 4 weeks of age and weighing at least 3 kg. The commercial opportunity is strongest in pediatric HIV, global differentiated formulations, and follow-on products that improve taste, portability, dosing accuracy, or access in low-resource settings.

The product’s excipient strategy is commercially relevant because pediatric antiretroviral adherence depends on administration convenience and palatability. The main competitive risks are generic dolutegravir products, alternative pediatric dispersible tablets, fixed-dose combinations, and future long-acting formulations rather than biosimilars.

What is TIVICAY PD and who manufactures it?

TIVICAY PD is a pediatric formulation of dolutegravir sodium, an HIV-1 integrase strand transfer inhibitor. ViiV Healthcare markets the product in the United States; GlaxoSmithKline, Pfizer and Shionogi are the principal corporate entities associated with the ViiV HIV business and dolutegravir development history.

The product is approved as 5 mg tablets for oral suspension. The tablets are dispersed in drinking water before administration. The FDA label permits administration to pediatric patients weighing at least 3 kg, subject to age, weight and treatment-specific dosing instructions.[1]

TIVICAY PD product profile

Attribute	Product characteristic
Active ingredient	Dolutegravir sodium
Strength	5 mg dolutegravir per tablet
Dosage form	Tablet for oral suspension
Route	Oral
Primary population	Pediatric patients with HIV-1
Minimum labeled weight	3 kg
Manufacturer	ViiV Healthcare
Administration	Disperse tablets in water before oral administration
Therapeutic class	Integrase strand transfer inhibitor
Regulatory pathway	FDA-approved new drug application
Biosimilar relevance	None; this is a small-molecule drug
Main substitution risk	Generic or alternative pediatric dolutegravir products

What excipients are used in TIVICAY PD?

The TIVICAY PD inactive ingredient system includes mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, sucralose and strawberry cream flavor.[1] The formulation combines fillers, a binder, a disintegrant, a lubricant, a sweetener and a flavoring system.

Excipient	Likely functional role	Commercial formulation significance
Mannitol	Diluent and mouthfeel modifier	Supports palatability and a cooling oral sensation
Microcrystalline cellulose	Filler and compression aid	Provides tablet structure and manufacturability
Povidone K29/32	Binder	Improves granule and tablet integrity
Sodium starch glycolate	Superdisintegrant	Promotes rapid dispersion in water
Sodium stearyl fumarate	Lubricant	Supports tablet ejection with less hydrophobicity than some conventional lubricants
Sucralose	High-intensity sweetener	Reduces bitterness from dolutegravir
Strawberry cream flavor	Flavor and taste-masking component	Improves pediatric acceptability

The product does not rely on a liquid suspension vehicle, preservative system or refrigeration-dependent formulation. That reduces packaging, transport and stability burdens relative to a ready-to-use pediatric liquid.

Why mannitol matters in the formulation

Mannitol is useful in pediatric oral products because it can improve mouthfeel and reduce the heavy or sticky sensation associated with some polyol systems. It also has broad pharmaceutical availability and established regulatory use.

Its limitations include potential sensitivity to moisture and polymorphic behavior. A manufacturer pursuing a follow-on product would need to control particle size, grade, water activity and compression behavior. These parameters can affect dispersion time, tablet hardness and dose uniformity.

Why sodium starch glycolate matters

Sodium starch glycolate is the primary performance excipient for rapid tablet breakup. In a tablet intended for dispersion before dosing, the target is not conventional swallowable-tablet disintegration alone. The product must disperse consistently in the labeled water volume without producing persistent clumps or excessive sedimentation.

Potential design-around opportunities include crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose or combinations of disintegrants. A substitute must preserve dispersion performance without increasing friability, grittiness or dose variability.

Why sucralose and flavor are commercially important

Dolutegravir has a bitter taste profile that can create pediatric adherence problems. Sucralose and strawberry cream flavor address the sensory barrier directly. Taste masking is often more difficult in a dispersed tablet than in a coated tablet because the active ingredient becomes available in the mouth after dispersion.

A competitor could pursue:

• A different flavor system, such as berry, vanilla or fruit blend.
• A higher-performance sweetener combination.
• Polymer-based taste masking.
• Ion exchange or lipid-based encapsulation.
• A mini-tablet or granule dosage form with reduced oral exposure.
• A dispersible fixed-dose combination with improved overall taste.

The commercial challenge is balancing masking performance with rapid dispersion. Hydrophobic coatings or encapsulation can delay wetting and create dose-uniformity problems.

How does the TIVICAY PD excipient strategy support pediatric use?

TIVICAY PD uses a dry, dispersible tablet rather than a conventional oral solution. That design addresses several pediatric and supply-chain requirements.

First, the product supports weight-based dosing by allowing multiple 5 mg tablets to be dispersed and administered according to the prescribed dose. Second, dry tablets generally have lower shipping volume and fewer microbiological risks than aqueous liquids. Third, the dosage form avoids the need for a bottle, measuring syringe and preservative system at the point of use.

The strategy also creates administration constraints. Caregivers must use the correct number of tablets, the correct volume of water and the correct administration procedure. Residue left in the cup can reduce the delivered dose. These risks create opportunities for improved packaging and device integration.

Potential administration improvements

A follow-on product could compete through:

• Unit-dose sachets containing a premeasured tablet count.
• A dosing cup marked for the required water volume.
• A co-packaged oral syringe.
• A dispersible granule sachet.
• A tablet that disperses in a smaller volume.
• A flavored tablet that can be dispersed without a separate cup.
• Packaging with weight-band instructions printed on the dose unit.

These improvements may support product differentiation even when the active ingredient and core excipient functions remain similar.

What formulations are protected by TIVICAY PD?

The commercial protection for TIVICAY PD can arise from several layers:

1. Dolutegravir compound and salt protection.
2. Pediatric dosing and administration methods.
3. Dispersible tablet composition.
4. Taste-masking technology.
5. Specific excipient ratios or processing conditions.
6. Fixed-dose pediatric combinations.
7. Manufacturing controls that deliver defined dispersion or dissolution performance.
8. Packaging and administration systems.

The strongest formulation claims usually require more than a list of conventional excipients. A claim directed only to mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, sucralose and flavor may face obviousness and enablement challenges if the ingredients are used at conventional levels.

Stronger claim strategies would connect the excipient system to a measurable result, such as:

• A defined dispersion time.
• A narrow particle-size distribution after dispersion.
• Reduced bitterness at a specified pH.
• Improved dose recovery from the administration vessel.
• Enhanced stability under high humidity.
• Consistent content uniformity across pediatric dose bands.
• A specific dissolution profile.
• A defined level of residual active ingredient in the dispersion vessel.

What is the FDA and Orange Book status of TIVICAY PD?

TIVICAY PD received FDA approval in 2020 under NDA 213983.[2] It is a small-molecule prescription product, not a biologic, so the relevant follow-on pathway is an abbreviated new drug application rather than a biosimilar application.

The FDA Orange Book identifies approved drug products, therapeutic equivalence information and applicable patent or exclusivity data. TIVICAY PD should be analyzed separately from the original TIVICAY tablet and from generic dolutegravir products because dosage form, strength, labeling and listed patents may differ.[3]

Exclusivity and generic-entry implications

The original TIVICAY approval predates TIVICAY PD. A later dosage-form approval may receive regulatory exclusivity tied to the new clinical investigation or product change, but that period does not automatically recreate broad market exclusivity for dolutegravir.

A generic applicant could target:

• The 5 mg pediatric dispersible tablet.
• A different pediatric dolutegravir dosage form.
• A generic product approved under a separate strength or administration method.
• An alternative pediatric formulation that avoids listed formulation claims.

The regulatory and commercial analysis must distinguish between approval of the same dosage form, approval of a therapeutically equivalent product, and approval of a different pediatric dosage form.

When does TIVICAY PD lose exclusivity?

TIVICAY PD’s effective loss of exclusivity depends on the interaction of Orange Book-listed patents, regulatory exclusivity, pediatric extensions and the timing of any Paragraph IV certifications.

A reliable launch date cannot be inferred solely from the 2020 approval date. Patent term, patent-term adjustment, pediatric exclusivity and litigation injunctions can change the date on which an ANDA applicant may obtain approval or launch.

Paragraph IV challenge risk

The most material Paragraph IV risk is likely to arise from a generic applicant targeting the pediatric dispersible dosage form or a listed formulation patent. A challenge to the active ingredient’s broader protection would have wider commercial consequences, but it may not be necessary for a generic company seeking a pediatric product.

Key litigation triggers include:

• A Paragraph IV notice concerning a listed TIVICAY PD patent.
• A suit filed within 45 days of notice.
• A potential 30-month approval stay.
• A settlement allowing an agreed launch date.
• A judgment invalidating, unenforceable or non-infringed claims.
• A later generic approval that avoids the asserted claims.

No biosimilar litigation pathway applies because dolutegravir is a chemically synthesized small molecule.

How strong is the TIVICAY PD patent estate?

The estate is strongest where it combines active-ingredient protection with formulation, pediatric-use and manufacturing claims. It is weaker where protection depends only on conventional excipients or a broad list of standard tablet ingredients.

Protection layer	Strategic value	Generic vulnerability
Dolutegravir compound claims	High	Depends on remaining term and claim validity
Pediatric use claims	Medium to high	May not block all non-infringing adult or alternative-use products
Dispersible tablet claims	Medium	Vulnerable to formulation design-around
Taste-masking claims	Medium	Strength depends on technical data and claim specificity
Excipient-combination claims	Low to medium	Conventional ingredients may face obviousness attacks
Process claims	Medium	Difficult to enforce without manufacturing evidence
Packaging and dosing-device claims	Low to medium	Can differentiate product but may not block core generic entry

The excipient estate is commercially useful when it is linked to product performance. It is less defensible when it merely recites common pharmaceutical excipients without a demonstrated technical effect.

What commercial opportunities exist for TIVICAY PD excipients?

Pediatric HIV combination products

The largest opportunity is integration into pediatric fixed-dose combinations. Dolutegravir is already central to modern HIV treatment, and a better-tasting dispersible combination could reduce pill burden and simplify caregiver administration.

Potential active ingredients include nucleoside reverse transcriptase inhibitors used in pediatric HIV regimens. Combination products must manage chemical compatibility, taste interactions, dissolution behavior and regulatory dose flexibility.

Low-resource and global-health markets

A dry dispersible tablet can be attractive in markets with limited cold-chain capacity, inconsistent water quality and long distribution routes. The commercial advantage depends on:

• High humidity stability.
• Robust blister packaging.
• Clear water and administration instructions.
• Affordable excipient sourcing.
• Simple dose-band packaging.
• Compatibility with national HIV procurement programs.

Mannitol, cellulose, povidone and starch-based excipients are widely sourced. Flavor and specialized taste-masking materials may create higher cost or supply-chain concentration.

Taste-masked pediatric generics

A generic competitor can differentiate through better taste rather than lower price alone. A successful formulation would need to demonstrate acceptable sensory performance while maintaining bioequivalence and rapid dispersion.

The commercial opportunity is strongest where caregivers currently use crushed adult tablets, compounded liquids or products with poor acceptability. Those alternatives create a basis for switching even when a generic tablet has limited price differentiation.

Improved dose-delivery systems

A tablet and administration device sold together could address the risk of dosing errors. Opportunities include unit-dose packaging, calibrated cups, oral syringes and weight-band labeling. Device-linked products may generate additional intellectual-property claims and reduce substitution if the delivery system is integrated into the label.

Contract manufacturing and excipient supply

Suppliers can pursue contracts for:

• Direct-compression mannitol grades.
• Low-moisture microcrystalline cellulose.
• Pediatric taste-masking systems.
• Rapid-disintegration platforms.
• Pharmaceutical strawberry or fruit flavor systems.
• High-barrier blister films.
• Small-batch pediatric tablet manufacturing.

The most defensible supplier position would combine excipient supply with formulation development, analytical testing and scale-up support.

How does TIVICAY PD compare with alternative pediatric dolutegravir products?

Product approach	Advantages	Limitations
TIVICAY PD dispersible tablet	Established FDA-approved product; dry dosage form; flexible pediatric dosing	Requires water, caregiver preparation and taste management
Conventional dolutegravir tablet crushed for children	Low technical complexity	Off-label manipulation; dose and palatability concerns
Pediatric oral liquid	Easy administration for some children	Higher volume, preservative needs and stability burden
Dispersible fixed-dose combination	Lower pill burden and simplified regimen	More complex compatibility, taste and dose design
Granule or sachet product	Portable and potentially dose-flexible	Packaging cost and powder-handling requirements
Long-acting injectable therapy	Avoids daily oral administration	Different clinical eligibility, administration and access requirements

TIVICAY PD has a stronger regulatory and clinical position than improvised crushed-tablet use, but a well-designed fixed-dose combination or taste-masked generic could compete effectively on convenience and cost.

What revenue exposure does TIVICAY PD create for ViiV?

ViiV does not generally disclose standalone global revenue for TIVICAY PD. Revenue exposure is therefore better assessed through the broader dolutegravir franchise, which includes TIVICAY, Triumeq, Dovato and pediatric formulations.

The product’s direct revenue is likely smaller than adult dolutegravir products, but its strategic value is higher in pediatric treatment access and regimen continuity. A pediatric product can protect prescriber and procurement relationships even when its direct sales are modest.

Commercial exposure is concentrated in four areas:

1. Pediatric formulary retention.
2. Government and global-health procurement.
3. Transition of children from pediatric to adult dolutegravir products.
4. Brand protection against low-cost pediatric generics and fixed-dose alternatives.

What manufacturing and IP barriers affect competitors?

The main manufacturing barriers are not unusual raw materials. They are process control and product-performance requirements.

A competing product must control:

• Active-ingredient content uniformity at low tablet strength.
• Tablet hardness and friability.
• Rapid dispersion.
• Taste and mouthfeel.
• Moisture uptake.
• Flavor stability.
• Dose recovery after administration.
• Packaging protection during transport.
• Bioequivalence against the reference product.

Dolutegravir is potent relative to the tablet mass, which makes low-dose content uniformity important. The formulation also has to withstand the mechanical and environmental conditions associated with pediatric and global-health distribution.

The principal IP barriers are likely to involve claims covering the active ingredient, pediatric use, dosage form, administration method and formulation performance. A competitor may avoid some claims by changing the disintegrant, flavor, sweetener, granulation process, tablet geometry or packaging. Such changes can introduce new development and regulatory risk.

What settlement agreements or litigation affect TIVICAY PD?

Public commercial analysis should separate litigation involving dolutegravir generally from litigation specifically directed to TIVICAY PD. Adult TIVICAY, combination products and pediatric dispersible tablets may have different patents, defendants and settlement terms.

A Paragraph IV settlement could establish an authorized-generic arrangement, an agreed generic launch date, a license to selected patents or restrictions on the formulation and labeling. No settlement should be assumed to apply to TIVICAY PD unless the agreement expressly covers the relevant NDA, patents and dosage form.

Key Takeaways

• TIVICAY PD uses a conventional but strategically coordinated excipient system built around mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, sucralose and strawberry cream flavor.
• The principal formulation objectives are rapid dispersion, taste masking, tablet integrity, low moisture burden and pediatric dose flexibility.
• The strongest commercial opportunity is a better-tasting, lower-cost pediatric dolutegravir product or fixed-dose combination.
• The strongest formulation patents would link excipient composition to measurable performance, not merely recite common inactive ingredients.
• TIVICAY PD is exposed to ANDA-based generic competition, not biosimilar competition.
• Global-health markets favor dry, stable and transportable pediatric products, but packaging and caregiver administration remain important design constraints.
• Product-level revenue is not separately disclosed, so commercial exposure should be evaluated through the wider dolutegravir franchise and pediatric formulary position.
• Orange Book patents, Paragraph IV notices and any settlement agreements should be assessed by NDA and dosage form rather than by the broader TIVICAY brand alone.

FAQs

Can TIVICAY PD tablets be mixed with food?

The FDA labeling provides specific administration instructions involving dispersion in water. Food administration should follow the approved prescribing information because food, mineral supplements and cation-containing products can affect dolutegravir exposure.[1]

Which excipient is most important for TIVICAY PD dispersion?

Sodium starch glycolate is the principal disintegrant supporting tablet breakup, while mannitol and microcrystalline cellulose provide much of the tablet’s physical structure and mouthfeel.

Could a generic replace strawberry cream flavor with another flavor?

Potentially, subject to formulation performance, labeling, bioequivalence and intellectual-property constraints. A flavor change may help avoid a narrow composition claim, but it does not by itself avoid active-ingredient or method-of-use patents.

Is a pediatric dolutegravir liquid commercially preferable to TIVICAY PD?

A liquid may simplify administration for some infants, but it usually creates higher stability, packaging, preservative, shipping-volume and dose-measurement burdens. A dry dispersible tablet is often more suitable for broad distribution if caregivers can prepare it accurately.

Do TIVICAY PD excipients create allergen or regulatory barriers?

The listed excipients are widely used pharmaceutical ingredients, but flavor components and regional excipient requirements must be reviewed for local labeling, allergen disclosure, pediatric acceptability and procurement standards.

References

1. U.S. Food and Drug Administration. (2023). TIVICAY PD (dolutegravir) tablets for oral suspension: Prescribing information. ViiV Healthcare.

2. U.S. Food and Drug Administration. (2020). Approval letter for TIVICAY PD, NDA 213983. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm